EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center

Chun Ho Wong, Kimberly Hang Tsoi, Jingya Jane Pu, Nancy Su Jiang, Stacey Sheung Yi Chan, Connie Hong Nin Loong, Xincheng Zou, Carol Ho Yi Fong, Eunice Ka Hong Leung, Alan Chun Hong Lee, Chi Ho Lee, Kathryn Choon Beng Tan und 3 weitere

Endocrinology and Metabolism · 31.12.2025 · 40 (6) · 974-990

DOI: 10.3803/enm.2024.2262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.12.2025. Verfasst von Chun Ho Wong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hon…. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We investigated osteoporosis management strategies and clinical outcomes following the occurrence of medicationrelated osteonecrosis of the jaw (MRONJ).

Methods

We retrospectively studied individuals diagnosed with MRONJ during osteoporosis treatment who were managed in the Osteoporosis Center or the Oral Maxillofacial Surgery & Dental Unit at Queen Mary Hospital in Hong Kong between 2010 and 2022. We examined subsequent osteoporosis management plans, fracture events, and bone mineral density (BMD).

Results

Thirty-six individuals were included (mean age, 78.5 years; 94.4% women). The estimated prevalence of MRONJ was 0.26%. All patients had been exposed to bisphosphonates, and seven had also received denosumab before MRONJ. Following MRONJ, only 14 individuals continued anti-osteoporosis treatment, a decision influenced by a higher fracture probability at MRONJ onset. The most common regimen was a teriparatide-raloxifene sequence (n=8): three patients achieved stable BMD, four achieved improving BMD, and one exhibited a mixed response. The patient with a mixed BMD response had also been treated with denosumab. Six patients sustained incident fractures after MRONJ, and these patients had lower BMD T-scores than their counterparts. Two patients experienced MRONJ recurrence, which was associated with the resumption of bisphosphonate or denosumab therapy after MRONJ. These patients had higher BMD T-scores than those who did not experience MRONJ recurrence.

Conclusion

MRONJ is challenging because high fracture risk necessitates discontinuation of antiresorptive agents. Teriparatide followed by raloxifene may be a reasonable regimen. Individualised decisions in osteoporosis management after MRONJ are required to balance fracture risk reduction with minimising MRONJ recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisBone Density Conservation AgentsBisphosphonate-Associated Osteonecrosis of the JawHumansFemaleMaleAgedRetrospective StudiesAged, 80 and overTertiary Care CentersBone DensityDenosumabHong KongFollow-Up StudiesMiddle AgedPrognosisDiphosphonates

Stichwörter der Autor:innen

BisphosphonateBone mineral densityDenosumabFractureOsteonecrosis of jawOsteoporosis

Substanzen

Bone Density Conservation AgentsDenosumabDiphosphonates

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
  • Division of Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, Hong Kong.

Zitieren

APA

Wong, C. H., Tsoi, K. H., Pu, J. J., Jiang, N. S., Chan, S. S. Y., Loong, C. H. N., Zou, X., Fong, C. H. Y., Leung, E. K. H., Lee, A. C. H., Lee, C. H., Tan, K. C. B., Woo, Y. C., Su, Y. X., & Lui, D. T. W. (2025). Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center. Endocrinology and Metabolism, 40(6), 974-990. https://doi.org/10.3803/enm.2024.2262

Vancouver

Wong CH, Tsoi KH, Pu JJ, Jiang NS, Chan SSY, Loong CHN, et al. Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center. Endocrinology and Metabolism. 2025;40(6):974-990. doi:10.3803/enm.2024.2262

BibTeX
@article{Wong2025,
  author = {Wong, Chun Ho and Tsoi, Kimberly Hang and Pu, Jingya Jane and Jiang, Nancy Su and Chan, Stacey Sheung Yi and Loong, Connie Hong Nin and Zou, Xincheng and Fong, Carol Ho Yi and Leung, Eunice Ka Hong and Lee, Alan Chun Hong and Lee, Chi Ho and Tan, Kathryn Choon Beng and Woo, Yu Cho and Su, Yu-Xiong and Lui, David Tak Wai},
  title = {Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center},
  journal = {Endocrinology and Metabolism},
  year = {2025},
  volume = {40},
  number = {6},
  pages = {974--990},
  doi = {10.3803/enm.2024.2262}
}
Kostenlos starten →